Lineage plasticity, the ability of cells to transition from one committed developmental pathway
to another, has been proposed as a source of intratumoural heterogeneity and of tumour …

Small cell lung cancer (SCLC) is an aggressive malignancy that includes subtypes defined
by differential expression of ASCL1, NEUROD1, and POU2F3 (SCLC-A, -N, and -P, …

Introduction EGFR-mutant lung cancers are clinically and genomically heterogeneous with
concurrent RB transcriptional corepressor 1 (RB1)/tumor protein p53 (TP53) alterations …

Introduction SCLC is a highly aggressive neuroendocrine tumor that is characterized by early
acquired therapeutic resistance and modest benefit from immune checkpoint blockade (ICB…

Concurrent loss-of-function mutations in STK11 and KEAP1 in lung adenocarcinoma (LUAD)
are associated with aggressive tumor growth, resistance to available therapies, and early …

Neuroendocrine neoplasms (NENs) can develop in almost any organ and span a spectrum
from well-differentiated and indolent neuroendocrine tumours (NETs) to poorly differentiated …

Paired single-cell RNA and T cell receptor sequencing (scRNA/TCR-seq) has allowed for
enhanced resolution of clonal T cell dynamics in cancer. Here, we report a scRNA/TCR-seq …

While regulatory T (T reg ) cells are traditionally viewed as professional suppressors of antigen
presenting cells and effector T cells in both autoimmunity and cancer, recent findings of …

Improved identification of anti-tumor T cells is needed to advance cancer immunotherapies.
CD39 expression is a promising surrogate of tumor-reactive CD8 + T cells. Here, we …

Background Lung cancer remains the most common cause of cancer-related death, with a 5-year
survival rate of only 18%. In recent years, the development of targeted …